Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

PDSB
PDS Biotechnology Corporation Common Stock
stock NASDAQ

At Close
Dec 26, 2025 3:55:05 PM EST
0.9000USD+0.437%(+0.0039)667,985
0.00Bid   0.00Ask   0.0000Spread
Pre-market
Dec 26, 2025 8:20:30 AM EST
0.8934USD+0.011%(+0.0001)100
After-hours
Dec 26, 2025 4:11:30 PM EST
0.8843USD-1.438%(-0.0129)345
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
08:11AM EST  PDS Biotech Announces Preclinical Data For PDS0202 Universal Influenza Vaccine   Benzinga
08:00AM EST  PDS Biotech Announces Preclinical Data for PDS0202 Universal   GlobeNewswire Inc
Jan 18, 2022
08:00AM EST  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune and Infectimune T-cell activating technologies respectively, today announced that its management will present at the B. Riley Securities Virtual Oncology Conference on January 28, 2022.   GlobeNewswire Inc
Jan 12, 2022
08:00AM EST  PDS Biotech Announces Presentation of PDS0101 Data at the 2022   GlobeNewswire Inc
Jan 10, 2022
07:00AM EST  PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy   GlobeNewswire Inc
Jan 5, 2022
08:00AM EST  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that its management will present at the H.C. Wainwright Bioconnect Virtual Conference.   GlobeNewswire Inc
Dec 23, 2021
04:00PM EST  PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule   GlobeNewswire Inc
Dec 6, 2021
08:32AM EST  PDS Biotech Announces The Reopening Of Recruitment In National Cancer Institute-Led Phase 2 Clinical Trial Of PDS0101-Based Combination   Benzinga
08:30AM EST  PDS Biotech Provides Recruitment update for National Cancer   GlobeNewswire Inc
Nov 10, 2021
08:23AM EST  The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance   Benzinga
07:17AM EST  PDS Biotechnology Q3 EPS $(0.24) Misses $(0.20) Estimate   Benzinga
07:00AM EST  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, will discuss its financial results for the quarter ended September 30, 2021 and provide a business update on its conference call today.   GlobeNewswire Inc
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Nov 8, 2021
08:37AM EST  PDS Biotech Reports Licensing Deal With National Cancer Institute For Intellectual Property Related To NCI's Proprietary Tumor-Associated, Immunologically Active T-Cell Receptor Gamma Alternate Reading Frame Protein, No Terms Disclosed   Benzinga
08:30AM EST  PDS Biotechnology Licenses Protein for the Treatment of Acute   GlobeNewswire Inc
Nov 1, 2021
08:31AM EDT  PDS Biotech Announces Agreement With University Of Georgia To License Novel Proteins For Versamune-Based Universal Flu Vaccine   Benzinga
08:30AM EDT  PDS Biotech Announces Agreement with University of Georgia to   GlobeNewswire Inc
Oct 27, 2021
08:50AM EDT  PDS Biotech Chief Medical Officer, Lauren V. Wood, To Present At 2021 International Head And Neck Cancer Conference Nov. 2-4   Benzinga
08:30AM EDT  PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at   GlobeNewswire Inc
Oct 21, 2021
12:11PM EDT  PDS Biotech Reports National Cancer Institute-Led Phase 2 Trial Of PDS0101-Based Combo Was Temporarily Suspended For Recruitment, 'no safety or efficacy concerns'   Benzinga
12:11PM EDT  UPDATE: PDS Says 'The issue is not specific to the PDS0101 trial and is unrelated to any safety or efficacy concerns with the triple combination. The NCI anticipates that the issue should be resolved timely'   Benzinga
07:30AM EDT  PDS Biotech Provides Update on National Cancer Institute-Led Phase   GlobeNewswire Inc
Oct 13, 2021
04:30PM EDT  PDS Biotechnology Announces Conference Call and Webcast to Present   GlobeNewswire Inc
Oct 6, 2021
08:35AM EDT  PDS Biotechnology Names Matthew Hill As CFO   Benzinga
08:30AM EDT  PDS Biotechnology Welcomes Matthew Hill as Chief Financial Officer   GlobeNewswire Inc
Oct 4, 2021
08:42AM EDT  PDS Biotech Enrolls First Stage Of Checkpoint Inhibitor Nave Patient Arm Of Phase 2 Clinical Trial In Advanced HPV-16 Positive Head And Neck Cancer   Benzinga
08:40AM EDT  PDS Biotech Enrolls First Stage Of Patient Of Phase 2 Clinical Trial In Advanced HPV-16 Positive Head And Neck Cancer   RTTNews
08:30AM EDT  PDS Biotech Enrolls First Stage of Checkpoint Inhibitor   GlobeNewswire Inc
Sep 30, 2021
09:30AM EDT  From BZ's Small Cap Healthcare Conference: PDS Biotechnology Director & CEO, Frank Bedu-Addo Begins Speaking   Benzinga
Sep 27, 2021
08:36AM EDT  PDS Biotechnology To Present At Benzinga Healthcare Conference Sept. 30   Benzinga
08:30AM EDT  PDS Biotechnology Corporation (PDS Biotech or the Company, Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that its management will participate in the Benzinga Healthcare Small Cap Conference.   GlobeNewswire Inc
Sep 23, 2021
07:57AM EDT  The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data   Benzinga
Sep 22, 2021
08:30AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that its management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference.   GlobeNewswire Inc
Sep 20, 2021
08:31AM EDT  PDS Biotech Achieves Safety Requirement Milestone For First 12 Patients In VERSATILE-002 Phase 2 Combination Trial Of PDS0101-KEYTRUDAIn Advanced Head And Neck Cancer   Benzinga
08:30AM EDT  PDS Biotech Achieves Safety Requirement Milestone For the First 12   GlobeNewswire Inc
Sep 15, 2021
08:30AM EDT  PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule   GlobeNewswire Inc
Sep 13, 2021
08:30AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, announced today that its management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.   GlobeNewswire Inc
Sep 10, 2021
08:00AM EDT  The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test   Benzinga
Sep 9, 2021
08:52AM EDT  PDS Biotech Completes Enrollment Of Lead-In Safety Cohort In VERSATILE-002 Phase 2 Combination Trial Of PDS0101-KEYTRUDA In Recurrent Or Metastatic Head And Neck Cancer   Benzinga
08:44AM EDT  PDS Biotech Completes Enrollment Of Lead-In Safety Cohort In VERSATILE-002 Phase 2 Combination Trial Of PDS0101-KEYTRUDA   RTTNews
08:38AM EDT  PDS Biotech Completes Enrollment Of VERSATILE-002 Phase 2 Combination Trial Of PDS0101-KEYTRUDA   RTTNews
08:30AM EDT  PDS Biotech Completes Enrollment of Lead-In Safety Cohort in   GlobeNewswire Inc
Sep 7, 2021
08:30AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, announced today that its management will present at the HC Wainwright 23rd Annual Global Investment Conference.   GlobeNewswire Inc
Sep 3, 2021
07:31AM EDT  The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself   Benzinga
Sep 1, 2021
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
Aug 31, 2021
08:15AM EDT  The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical   Benzinga
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 26, 2021
08:09AM EDT  The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO   Benzinga
Aug 12, 2021
11:01AM EDT  HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $15   Benzinga
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
07:22AM EDT  PDS Biotechnology Q2 EPS $(0.03) Beats $(0.17) Estimate   Benzinga
07:05AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, will discuss its financial results for the quarter ended June 30, 2021 and provide a business update on its conference call today.   GlobeNewswire Inc
04:14AM EDT  Earnings Scheduled For August 12, 2021   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Jul 28, 2021
08:04AM EDT  PDS Biotechnology To Present Recent Phase 2 Human Clinical Data And Ongoing Oncology Programs At Investor Conference   Benzinga
08:00AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, announced today that its management team will present at several investor conferences listed below during the third quarter of 2021.   GlobeNewswire Inc
Jul 26, 2021
08:00AM EDT  PDS Biotechnology Announces Conference Call and Webcast to Present   GlobeNewswire Inc
Jul 1, 2021
08:43AM EDT  PDS Biotechnology Joins Russell Microcap Index   Benzinga
08:30AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, was added to the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective on June 28, according to the FTSE Russell website.   GlobeNewswire Inc
Jun 28, 2021
10:21AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021   Benzinga
08:01AM EDT  Cantor Fitzgerald Initiates Coverage On PDS Biotechnology with Overweight Rating, Announces Price Target of $25   Benzinga
Jun 18, 2021
05:30AM EDT  PDS Biotechnology Shares Trading Higher After Multiple Officers, Directors Report Shares Purchases in Form 4 Filings on Thursday   Benzinga
Jun 17, 2021
04:15PM EDT  PDS Biotechnology Corporation Announces Closing of Approximately   GlobeNewswire Inc
Jun 16, 2021
05:02AM EDT  44 Biggest Movers From Yesterday   Benzinga
Jun 15, 2021
02:56PM EDT  Mid-Afternoon Market Update: Nasdaq Down 100 Points; Clearside Biomedical Shares Spike Higher   Benzinga
12:03PM EDT  Mid-Day Market Update: Crude Oil Rises 1%; Sage Therapeutics Shares Slide   Benzinga
10:18AM EDT  Mid-Morning Market Update: Markets Open Lower; US Retail Sales Drop 1.3% In May   Benzinga
09:15AM EDT  PDS Biotech 5.29M Share Offering Priced At $8.50/Share   Benzinga
09:00AM EDT  PDS Biotech Prices Public Offering of Common Stock   GlobeNewswire Inc
08:07AM EDT  The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda   Benzinga
06:02AM EDT  A Peek Into The Markets: US Stock Futures Slightly Higher; Fed Meeting In Focus   Benzinga
Jun 14, 2021
04:04PM EDT  PDS Biotech Announces Proposed Common Stock Offering; Size Not Disclosed   Benzinga
04:02PM EDT  PDS Biotech Announces Proposed Offering of Common Stock   GlobeNewswire Inc
08:00AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage cancer immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced it will host an Oncology R&D Day for analysts, investors, and the scientific community on Wednesday, June 16th.   GlobeNewswire Inc
Jun 9, 2021
08:23AM EDT  Chardan Capital Maintains Buy on PDS Biotechnology, Raises Price Target to $15   Benzinga
Jun 8, 2021
09:17AM EDT  The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex   Benzinga
07:54AM EDT  CORRECTING AND REPLACING -- PDS Biotech Announces Release of   GlobeNewswire Inc
07:44AM EDT  PDS Biotech's Lead Versamune Program Achieves Overall Tumor Reduction of 67% In HPV16 Positive Cancer Patients   Benzinga
06:44AM EDT  PDS Biotech Earlier Highlighted Release of Interim Data For PDS0101 In NCI-Led Phase 2 Clinical Study In Oral Presentation At ASCO 2021 Annual Meeting   Benzinga
06:07AM EDT  PDS Biotechnology Announces Presentation Of Interim Data From Phase 2 Trial At ASCO   RTTNews
06:00AM EDT  PDS Biotech Announces Release of Interim Data for PDS0101 in   GlobeNewswire Inc
Jun 7, 2021
08:05AM EDT  PDS Biotechnology Set To Join Russell Microcap Index   Benzinga
Jun 3, 2021
08:59AM EDT  PDS Biotechnology Announces Protocol Amendment To Expand Its Phase 2 VERSATILE-002 Study   RTTNews
08:55AM EDT  PDS Biotechnology Says Expands VERSATILE-002 Study Of PDS0101, KEYTRUDA In Advanced Head And Neck Cancer To Include Patients Who Have Failed Prior Treatment With Checkpoint Inhibitors   Benzinga
08:54AM EDT  PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and   GlobeNewswire Inc
Jun 2, 2021
07:41AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
06:13AM EDT  HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Raises Price Target to $20   Benzinga
Jun 1, 2021
08:28AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced it will host an Oncology R&D Day for analysts, investors, and the scientific community from 8:00 10:00 AM ET on Wednesday, June 16th.   GlobeNewswire Inc
May 28, 2021
08:02AM EDT  The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq   Benzinga
May 27, 2021
08:24AM EDT  The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs   Benzinga
07:30AM EDT  PDS Biotechnology Establishes Partnership With Head and Neck   GlobeNewswire Inc
May 25, 2021
07:53AM EDT  The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal   Benzinga
May 24, 2021
08:07AM EDT  PDS Biotech to Host Company Conference Call Following Oral   GlobeNewswire Inc
May 21, 2021
07:26AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying   Benzinga
May 20, 2021
02:31PM EDT  Mid-Afternoon Market Update: Dow Jumps 230 Points; Kohl's Shares Plummet   Benzinga
12:21PM EDT  Mid-Day Market Update: Nasdaq Surges 200 Points; Black Diamond Therapeutics Shares Slide   Benzinga
08:29AM EDT  Chardan Capital Maintains Buy on PDS Biotechnology, Raises Price Target to $11   Benzinga
08:05AM EDT  PDS Biotech Announces Release Of Abstract For PDS0101 In NCI-Led Phase 2 Clinical Study For Oral Presentation At 2021 ASCO Meeting   Benzinga
08:00AM EDT  PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led   GlobeNewswire Inc
May 19, 2021
05:02PM EDT  PDS Biotech Shares Move Higher After Hours As Traders Circulate Abstract From American Society Of Clinical Oncology Website   Benzinga
May 18, 2021
08:00AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced the appointment of Dr. Olivera Finn and Dr. Mark Frohlich to its Scientific Advisory Board.   GlobeNewswire Inc
May 17, 2021
08:18AM EDT  PDS Biotech Receives $4.5M After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program   Benzinga
08:00AM EDT  PDS Biotech Receives $4.5M After Selling Its Net Operating Loss   GlobeNewswire Inc
May 13, 2021
01:28PM EDT  PDS Biotechnology shares were trading higher after the company reported better-than-expected Q1 EPS results.   Benzinga
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
07:12AM EDT  PDS Biotechnology Q1 EPS $(0.14) Beats $(0.19) Estimate   Benzinga
07:00AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, will discuss its financial results for the quarter ended March 31, 2021 and provide a business update on its conference call today.   GlobeNewswire Inc
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
May 12, 2021
08:00AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced their participation in Noble Capital Markets C-Suite Interview Series, presented by Channelchek.   GlobeNewswire Inc
May 3, 2021
10:27AM EDT  PDS Biotech Advances the Fight Against Cancer with its Versamune Platform   Benzinga
Apr 29, 2021
08:31AM EDT  PDS Biotech Announces Oral Presentation Of PDS0101 Data By National Cancer Institute At 2021 American Society of Clinical Oncology Annual Meeting   Benzinga
08:30AM EDT  PDS Biotech Announces Oral Presentation of PDS0101 Data by the   GlobeNewswire Inc
Apr 26, 2021
04:15PM EDT  PDS Biotechnology Announces Conference Call and Webcast for First   GlobeNewswire Inc
Apr 19, 2021
09:22AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced their participation in Noble Capital Markets Virtual Road Show Series, presented by Channelchek, scheduled for April 21, 2021.   GlobeNewswire Inc
Mar 25, 2021
02:45PM EDT  Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference   Benzinga
Mar 24, 2021
10:31AM EDT  From BZ Biotech Conference: PDS Biotechnology CEO Dr. Frank Bedu-Addo Says Killer T-Cells May Play An Important Role In Providing Immunity And Protection Against Infections   Benzinga
10:29AM EDT  From BZ Biotech Conference: PDS Biotechnology CEO Dr. Frank Bedu-Addo Says Co. Anticipates Commercialization Of PDS0203 In Brazil In 2023   Benzinga
10:25AM EDT  From BZ Biotech Conference: PDS Biotechnology CEO Dr. Frank Bedu-Addo Says Co. Expects Phase 3 COVID-19 Vaccine Trial Could Be Initiated Next Year   Benzinga
10:23AM EDT  From BZ Biotech Conference: PDS Biotechnology CEO Dr. Frank Bedu-Addo Says With Pending Results, Co. Believes PDS0203, Its Subunit Vaccine, Could Be Commercially Available in 2023; Says With Clinical Success, PDS0203 Could be competitive In Latin America   Benzinga
10:20AM EDT  From BZ Biotech Conference: PDS Biotechnology CEO Dr. Frank Bedu-Addo Says Kill T-Cells May Play An Important Role In Providing Immunity And Protection Against Infections   Benzinga
10:09AM EDT  From BZ Biotech Conference: PDS Biotechnology CEO Dr. Frank Bedu-Addo Says Co.'s Versamune-Based Immunotherapies Promote A Powerful M-Vivo Tumor-Specific CD8+ Killer T-Cell Response   Benzinga
Mar 23, 2021
07:12PM EDT  Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021   Benzinga
Mar 19, 2021
06:46AM EDT  HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Raises Price Target to $8   Benzinga
Mar 18, 2021
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
07:14AM EDT  PDS Biotechnology Reports FY20 EPS $(0.89) Up From $(1.44) YoY   Benzinga
07:07AM EDT  Earnings Scheduled For March 18, 2021   Benzinga
07:00AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced its financial results for the year ended December 31, 2020 and provided a business update.   GlobeNewswire Inc
Mar 14, 2021
08:14AM EDT  Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations   Benzinga
Mar 11, 2021
02:49PM EST  Mid-Afternoon Market Update: Dow Jumps Over 300 Points; Entera Bio Shares Gain   Benzinga
08:35AM EST  PDS Biotech Announces That Its COVID-19 Vaccine Consortium Received a Commitment From The MCTI To Fund Clinical Development and Commercialization Of A Versamune-Based COVID-19 Vaccine With An Award Of Up To ~$60M   Benzinga
08:30AM EST  PDS Biotech Announces that its COVID-19 Vaccine Consortium   GlobeNewswire Inc
Mar 8, 2021
04:30PM EST  PDS Biotechnology Announces Conference Call and Webcast for Fourth   GlobeNewswire Inc
Mar 3, 2021
04:30PM EST  PDS Biotech Announces Presentations in Upcoming Healthcare   GlobeNewswire Inc
Feb 22, 2021
08:33AM EST  PDS Biotechnology And Farmacore Biotechnology Announce Brazilian Pharmaceutical Company Blanver Has Joined Their Consortium To Develop And Commercialize A COVID-19 Vaccine In Latin America   Benzinga
08:30AM EST  PDS Biotech and Farmacore Announce Blanver to Join Consortium to   GlobeNewswire Inc
Feb 10, 2021
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
02:54AM EST  Today's Daily Dose brings you news about KalVista's hereditary angioedema trial results, Heat Biologics' encouraging data from its phase II trial of HS-110 in non-small cell lung cancer, Gamida's presentation of full efficacy and safety results of Omidubicel in patients with hematologic malignancies and Neovasc regaining Nasdaq compliance.   RTTNews
Feb 3, 2021
12:42PM EST  PDS Biotechnology Moves Forward With Full Enrollment In PDS0101 Trial In HPV-Associated Cancers, Shares Retreat   Benzinga
09:12AM EST  PDS Biotech Reports Prelim. Efficacy Achievement In Phase 2 Combo Trial Of PDS0101 Led By National Cancer Institute   Benzinga
09:00AM EST  PDS Biotech Announces Preliminary Efficacy Achievement in Phase 2   GlobeNewswire Inc
Jan 14, 2021
08:37AM EST  PDS Biotech Releases White Paper Detailing Potential Of Versamune Platform In Overcoming A Major Limitation Of Immuno-Oncology   Benzinga
08:30AM EST  PDS Biotech Releases White Paper Detailing the Potential of the   GlobeNewswire Inc
Jan 6, 2021
08:30AM EST  PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing   GlobeNewswire Inc
Jan 5, 2021
08:45AM EST  PDS Biotech Announces Participation in H.C. Wainwright BioConnect   GlobeNewswire Inc
Dec 21, 2020
08:38AM EST  PDS Biotech Announces Mount Sinai Publication Of Studies Showing Superior Induction Of Antibodies By Versamune-Based COVID-19 Vaccine   Benzinga
08:30AM EST  PDS Biotech Announces Mount Sinai Publication of Studies Showing   GlobeNewswire Inc
Dec 9, 2020
08:39AM EST  PDS Biotechnology Appoints Seth Van Voorhees As CFO   RTTNews
08:35AM EST  PDS Biotech Names Seth Van Voorhees CFO   Benzinga
08:30AM EST  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced the appointment of Seth Van Voorhees, Ph.D. as its new Chief Financial Officer effective January 1, 2021.   GlobeNewswire Inc
Nov 16, 2020
08:35AM EST  PDS Biotech Announces New, Broad Versamune Platform Patent Claims   Benzinga
08:30AM EST  PDS Biotech Announces New and Broad Versamune Platform   GlobeNewswire Inc
Nov 11, 2020
04:05PM EST  PDS Biotechnology Q3 EPS $(0.23) Misses $(0.20) Estimate   Benzinga
04:05PM EST  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced its financial results for the third quarter ended September 30, 2020 and provided a business update.   GlobeNewswire Inc
04:09AM EST  Earnings Scheduled For November 11, 2020   Benzinga
Nov 10, 2020
04:05PM EST  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced progress on its co-development program with Farmacore Biotechnology for a Versamune-based vaccine aimed at preventing COVID-19 infection.   GlobeNewswire Inc
Nov 9, 2020
04:23PM EST  PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA in Recurrent/Metastatic Head and Neck Cancer in Collaboration with Merck   Benzinga
04:05PM EST  PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of   GlobeNewswire Inc
Oct 26, 2020
08:31AM EDT  PDS Biotech Announces Initiation Of Phase 2 Trial Of PDS0101 In Combination With Standard Of Care Chemoradiotherapy In Advanced Cervical Cancer   Benzinga
08:30AM EDT  PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 in   GlobeNewswire Inc
Oct 1, 2020
08:30AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced their participation in Noble Capital Markets Virtual Road Show Series, presented by Channelchek, scheduled for October 6, 2020.   GlobeNewswire Inc
Sep 28, 2020
08:43AM EDT  PDS Biotechnology To Present Results From Its Phase 1 Trial Of PDS0101   RTTNews
08:35AM EDT  PDS Biotechnologoy To Present Results From Phase 1 Trial Of PDS0101, Phase 2 Clinical Strategy In Patients With Advanced HPV-Associated Malignancies   Benzinga
08:30AM EDT  PDS Biotechnology to Present Results from its Phase 1 Trial of   GlobeNewswire Inc
Sep 8, 2020
04:05PM EDT  PDS Biotechnology to Participate in Upcoming Healthcare Investor   GlobeNewswire Inc
Aug 31, 2020
08:30AM EDT  PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced its participation in Noble Capital Markets C-Suite Interview Series, presented by Channelchek.   GlobeNewswire Inc
Aug 21, 2020
09:54AM EDT  PDS Biotechnology Shares Move Higher As Traders Circulate JRS Report That Versamune Coronavirus Vaccine Being Developed By Co Has Received Support Of Financier Of Studies, Projects   Benzinga
Aug 13, 2020
04:05PM EDT  PDS Biotechnology Corporation Announces Closing of Approx. $19   GlobeNewswire Inc
08:18AM EDT  The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller   Benzinga
06:05AM EDT  PDS Biotechnology Q2 EPS $(0.19) Beats $(0.23) Estimate   Benzinga
06:00AM EDT  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced its financial results for the second quarter ended June 30, 2020 and provided a business update.   GlobeNewswire Inc
04:03AM EDT  Earnings Scheduled For August 13, 2020   Benzinga
Aug 11, 2020
09:09AM EDT  PDS Biotech Prices 6M Share Common Stock Offering $2.75/Share   Benzinga
09:05AM EDT  PDS Biotechnology Corporation Announces Pricing of $16.5 Million   GlobeNewswire Inc
Aug 10, 2020
04:18PM EDT  PDS Biotechnology Announces That It Proposed A Common Stock Offering; No Details Disclosed   Benzinga
04:05PM EDT  PDS Biotechnology Corporation Announces Proposed Public Offering   GlobeNewswire Inc
Jul 27, 2020
10:03AM EDT  Shares of PDS Biotechnology Corp. (PDSB) are rising over 7% Monday morning, after the company announced robust preclinical data for its COVID-19 vaccine candidate, Versamune-CoV-2 (PDS0203).   RTTNews
08:30AM EDT  PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell   GlobeNewswire Inc
Jul 20, 2020
05:11AM EDT  80 Biggest Movers From Friday   Benzinga
Jul 14, 2020
08:39AM EDT  PDS Biotech Collaborator Granted NIAID Award To Accelerate Development Of Versamune-Based Universal Influenza Vaccine   Benzinga
08:30AM EDT  PDS Biotech Collaborator Granted NIAID Award to Accelerate   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC